Humacyte Q2 FY26 net loss narrows to $36.8 million; Symvess revenue more than quadruples to $406,000
HUMA•Clinical update
Dialysis access Phase 3 interim data showed ATEV beat AV fistula; sBLA filing planned in the second half of 2026.
Cash position and financing
Cash, cash equivalents and restricted cash totaled $80.3 million; June public offering raised $57.5 million in gross proceeds.
Quarterly financial results
Humacyte posted a net loss of $36.8 million; loss per share narrowed to $0.16 from $0.24.
Revenue rose 34.88% to $406,000; Symvess sales more than doubled to $406,000.
Operating loss narrowed to $27 million from $29.73 million; R&D expense fell to $18.14 million from $22.01 million.
